glp 1 agonist heart disease Mechanisms of GLP-1 Receptor Agonists in HFpEF: Exploring Weight-Dependent and Independent Drivers of Therapeutic Benefit Cardiovascular and mortality outcomes with
Description
To see how widespread use has become, RAND surveyed 8,793 Americans in April and May
Utilities and disutilities for attributes of injectable treatments for type 2 diabetes
With more GLP-1 options than ever before, choosing the right one can be difficult
If disease activity remains inadequately controlled, treatment should escalate to combination conventional synthetic DMARDs or biological agents following a treat-to-target approach
CRC Press
Int J Mol Sci (2019) 20(7):1584
